During the past decade, Affiliated Tumor Hospital of Xinjiang Medical University conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Affiliated Tumor Hospital of Xinjiang Medical University" #1 sponsor was "BeiGene" with 4 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Loxo Oncology, Inc." with 3 trials sponsored, "Betta Pharmaceuticals Co., Ltd." with 2 trials sponsored and "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 2 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Affiliated Tumor Hospital of Xinjiang Medical University" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "GeneCast Biotechnology Co., Ltd." with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Peking Union Medical College Hospital" with 2 trials as a collaborator and "Allist Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Affiliated Tumor Hospital of Xinjiang Medical University" are "Non-small Cell Lung Cancer" (4 trials), "Breast Cancer" (3 trials), "Extranodal NK-T-Cell Lymphoma, Nasal Type" (2 trials), "Gastric Cancer" (2 trials) and "Lymphoma, Mantle-Cell" (2 trials). Many other conditions were trialed in "Affiliated Tumor Hospital of Xinjiang Medical University" in a lesser frequency.

Most popular intervention types in "Affiliated Tumor Hospital of Xinjiang Medical University" are "Drug" (38 trials), "Biological" (3 trials), "Procedure" (2 trials), "Radiation" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Cisplatin" (6 trials), "Pembrolizumab" (4 trials), "Pemetrexed" (4 trials) and "Carboplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Affiliated Tumor Hospital of Xinjiang Medical University" are 36 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 27 active trials in "Affiliated Tumor Hospital of Xinjiang Medical University". 1 are not yet recruiting, 14 are recruiting, 11 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 5 completed trials in Affiliated Tumor Hospital of Xinjiang Medical University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Affiliated Tumor Hospital of Xinjiang Medical University, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".